Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Диагностика и лечение гломерулонефрита, обусловленного антителами к базальной мембране клубочка

Список литературы

  1. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013;65(1):1-11. doi:10.1002/art.37715
  2. Fisher M, Pusey CD, Vaughan RW, Rees AJ. Susceptibility to anti-glomerular basement membrane disease is strongly associated with HLA-DRB1 genes. Kidney Int. 1997;51(1):222-229. doi:10.1038/ki.1997.27
  3. Zhou X-J, Lv J-C, Yu L, et al. FCGR2B gene polymorphism rather than FCGR2A, FCGR3A and FCGR3B is associated with anti-GBM disease in Chinese. Nephrol Dial Transplant. 2010;25(1):97-101. doi:10.1093/ndt/gfp374
  4. Zhou X jie, Lv J cheng, Bu D fang, et al. Copy number variation of FCGR3A rather than FCGR3B and FCGR2B is associated with susceptibility to anti-GBM disease. Int Immunol. 2009;22(1):45-51. doi:10.1093/intimm/dxp113
  5. Persson U, Hertz JM, Carlsson M, et al. Patients with Goodpasture’s disease have two normal COL4A3 alleles encoding the NC1 domain of the type IV collagen α3 chain. Nephrol Dial Transplant. 2004;19(8):2030-2035. doi:10.1093/ndt/gfh3556.
  6. Savage CO, Pusey CD, Bowman C, Rees AJ, Lockwood CM. Antiglomerular basement membrane antibody mediated disease in the British Isles 1980-4. Br Med J (Clin Res Ed). 1986;292(6516):301-304. doi:10.1136/bmj.292.6516.301
  7. McAdoo SP, Pusey CD. Clustering of Anti-GBM Disease: Clues to an Environmental Trigger? Clin J Am Soc Nephrol. 2016;11(8):1324-1326. doi:10.2215/CJN.05580516
  8. Perez GO, Bjornsson S, Ross AH, Aamato J, Rothfield N. A mini-epidemic of Goodpasture’s syndrome clinical and immunological studies. Nephron. 1974;13(2):161-173. doi:10.1159/000180389
  9. Wilson CB, Smith RC. Goodpasture’s syndrome associated with influenza A2 virus infection. Ann Intern Med. 1972;76(1):91-94. doi:10.7326/0003-4819-76-1-91
  10. Gu Q-H, Xie L-J, Jia X-Y, et al. Fever and prodromal infections in anti-glomerular basement membrane disease. Nephrology (Carlton). 2018;23(5):476-482. doi:10.1111/nep.1304011.
  11. Donaghy M, Rees AJ. Cigarette smoking and lung haemorrhage in glomerulonephritis caused by autoantibodies to glomerular basement membrane. Lancet (London, England). 1983;2(8364):1390-1393.
  12. Bombassei GJ, Kaplan AA. The association between hydrocarbon exposure and anti- glomerular basement membrane antibody-mediated disease (Goodpasture’s syndrome). Am J Ind Med. 1992;21(2):141-153.
  13. Rutgers A, Slot M, van Paassen P, van Breda Vriesman P, Heeringa P, Tervaert JWC. Coexistence of anti-glomerular basement membrane antibodies and myeloperoxidase- ANCAs in crescentic glomerulonephritis. Am J Kidney Dis. 2005;46(2):253-262. doi:10.1053/j.ajkd.2005.05.003
  14. Jia X, Hu S, Chen J, et al. The clinical and immunological features of patients with combined anti-glomerular basement membrane disease and membranous nephropathy. Kidney Int. 2014;85(4):945-952. doi:10.1038/ki.2013.364
  15. Xenocostas A, Jothy S, Collins B, Loertscher R, Levy M. Anti–glomerular basement membrane glomerulonephritis after extracorporeal shock wave lithotripsy. Am J Kidney Dis. 1999;33(1):128-132. doi:10.1016/S0272-6386(99)70268-4
  16. Guerin V, Rabian C, Noel LH, et al. Anti-glomerular-basement-membrane disease after lithotripsy. Lancet (London, England). 1990;335(8693):856-857. doi:10.1016/0140- 6736(90)90971-7
  17. Clatworthy MR, Wallin EF, Jayne DR. Anti-glomerular basement membrane disease after alemtuzumab. N Engl J Med. 2008;359(7):768-769. doi:10.1056/NEJMc0800484
  18. Turner N, Mason PJ, Brown R, et al. Molecular cloning of the human Goodpasture antigen demonstrates it to be the alpha 3 chain of type IV collagen. J Clin Invest. 1992;89(2):592 - 601. doi:10.1172/JCI115625
  19. J Saus 1, J Wieslander, J P Langeveld, et al. Identification of the Goodpasture antigen as the alpha 3(IV) chain of collagen IV. J Biol Chem. 1988;263(26):13374-80.
  20. Pedchenko V, Bondar O, Fogo AB, et al. Molecular Architecture of the Goodpasture Autoantigen in Anti-GBM Nephritis. N Engl J Med. 2010;363(4):343-354. doi:10.1056/NEJMoa0910500
  21. Olson SW, Arbogast CB, Baker TP, et al. Asymptomatic autoantibodies associate with future anti-glomerular basement membrane disease. J Am Soc Nephrol. 2011;22(10):1946-1952. doi:10.1681/ASN.2010090928
  22. Salama AD, Chaudhry AN, Ryan JJ, et al. In Goodpasture’s disease, CD4(+) T cells escape thymic deletion and are reactive with the autoantigen alpha3(IV)NC1. J Am Soc Nephrol. 2001;12(9):1908-1915.
  23. Zou J, Hannier S, Cairns LS, et al. Healthy individuals have Goodpasture autoantigen - reactive T cells. J Am Soc Nephrol. 2008;19(2):396-404. doi:10.1681/ASN.2007050546
  24. Bolton WK, Innes DJ, Sturgill BC, Kaiser DL. T-cells and macrophages in rapidly progressive glomerulonephritis: clinicopathologic correlations. Kidney Int. 1987;32(6):869- 876. doi:10.1038/ki.1987.28825.
  25. Nolasco FE, Cameron JS, Hartley B, Coelho A, Hildreth G, Reuben R. Intraglomerular T cells and monocytes in nephritis: study with monoclonal antibodies. Kidney Int. 1987;31(5):1160-1166. doi:10.1038/ki.1987.123
  26. Canney M, O’Hara P V, McEvoy CM, et al. Spatial and Temporal Clustering of Anti- Glomerular Basement Membrane Disease. Clin J Am Soc Nephrol. 2016;11(8):1392-1399. doi:10.2215/CJN.13591215
  27. Jennette JC. Rapidly progressive crescentic glomerulonephritis. Kidney Int. 2003;63(3):1164-1177. doi:10.1046/j.1523-1755.2003.00843.x
  28. Hirayama K, Yamagata K, Kobayashi M, Koyama A. Anti-glomerular basement membrane antibody disease in Japan: part of the nationwide rapidly progressive glomerulonephritis survey in Japan. Clin Exp Nephrol. 2008;12(5):339-347. doi:10.1007/s10157-008-0051-829.
  29. Wilson CB, Dixon FJ. Anti-glomerular basement membrane antibody-induced glomerulonephritis. Kidney Int. 1973;3(2):74-89. Accessed February 8, 2018. http://www.ncbi.nlm.nih.gov/pubmed/4571918
  30. Cui Z, Zhao MH, Xin G, Wang HY. Characteristics and prognosis of Chinese patients with anti-glomerular basement membrane disease. Nephron - Clin Pract. 2005;99(2):c49-55. doi:10.1159/000083133
  31. Nasr SH, Collins AB, Alexander MP, et al. The clinicopathologic characteristics and outcome of atypical anti-glomerular basement membrane nephritis. Kidney Int. 2016;89(4):897-908. doi:10.1016/j.kint.2016.02.001
  32. Levy JB, Turner AN, Rees AJ, Pusey CD. Long-term outcome of anti-glomerular basement membrane antibody disease treated with plasma exchange and immunosuppression. Ann Intern Med. 2001;134(11):1033-1042. doi:10.7326/0003-4819-134-11-200106050-00009
  33. Lazor R, Bigay-Gamé L, Cottin V, et al. Alveolar hemorrhage in anti-basement membrane antibody disease: a series of 28 cases. Medicine (Baltimore). 2007;86(3):181-193. doi:10.1097/md.0b013e318067da5634.
  34. Ang C, Savige J, Dawborn J, et al. Anti-glomerular basement membrane (GBM)-antibody- mediated disease with normal renal function. Nephrol Dial Transplant. 1998;13(4):935-939. Accessed February 8, 2018. http://www.ncbi.nlm.nih.gov/pubmed/9568853
  35. Буланова М.Л., Потапов Д.В., Буланов Н.М., Лысенко Л.В. Атипичное течение болезни Гудпасчера: клиническое наблюдение и обзор литературы. Терапевтический архив. 2018;90(6):130-136. doi:10.26442/terarkh2018906130-136.
  36. Подзолков ВИ, Махнач ГК, Ишина ТИ, Пономарев АБ, Медведев ИД. К вопросу о сложности диагностики синдрома Гудпасчера. Терапевтический архив. 2019;91(3):64- 67.
  37. Мухин НА. Синдром Гудпасчера. Клиническая фармакология и терапия. 2012;21(5):39-44.
  38. Cмирнов А.В., Ватазин А.В. Клинические рекомендации. Хроническая болезнь почек. 2020. https://rusnephrology.org/wp-content/uploads/2020/12/CKD_final.pdf
  39. Sinico RA, Radice A, Corace C, Sabadini E, Bollini B, et al. Anti-glomerular basement membrane antibodies in the diagnosis of Goodpasture syndrome: a comparison of different assays. Nephrol Dial Transplant. 2006 Feb;21(2):397-401. doi: 10.1093/ndt/gfi230.
  40. Glassock RJ. Atypical anti-glomerular basement membrane disease: lessons learned. Clin Kidney J. 2016;9(5):653-656. doi:10.1093/ckj/sfw068
  41. Salama AD, Dougan T, Levy JB, et al. Goodpasture’s disease in the absence of circulating anti-glomerular basement membrane antibodies as detected by standard techniques. Am J Kidney Dis. 2002;39(6):1162-1167. doi:10.1053/ajkd.2002.33385
  42. McAdoo SP, Pusey CD. Anti-Glomerular Basement Membrane Disease. Clin J Am Soc Nephrol. 2017;12(7):1162-1172. doi:10.2215/CJN.0138021743.
  43. Moiseev S, Cohen Tervaert JW, Arimura Y, et al. 2020 international consensus on ANCA testing beyond systemic vasculitis. Autoimmun Rev. 2020;19(9):102618. doi:10.1016/j.autrev.2020.102618.
  44. Marques C, Carvelli J, Biard L, et al. Prognostic Factors in Anti-glomerular Basement Membrane Disease: A Multicenter Study of 119 Patients. Front Immunol. 2019;10. doi:10.3389/fimmu.2019.01665
  45. McAdoo SP, Pusey CD. Anti-Glomerular Basement Membrane Disease. Clin J Am Soc Nephrol. 2017;12(7):1162-1172. doi:10.2215/CJN.01380217
  46. Serra G, Brun AL, Toledano D, Cluzel P, Grenier PA. Thoracic involvement in systemic primary vasculitis: Radiological patterns and follow-up. JBR-BTR. 2014;97(2):57-68. doi:10.5334/jbr-btr.36
  47. Fischer EG, Lager DJ. Anti-glomerular basement membrane glomerulonephritis: A morphologic study of 80 cases. Am J Clin Pathol. 2006;125(3):445-450. doi:10.1309/NPTP4UKV7JU3ELMQ
  48. Смирнов АВ, Ватазин АВ, Голубев РВ. Клинические рекомендации. Острое повреждение почек. Published online 2020:1-142. https://rusnephrology.org/wp- content/uploads/2020/12/AKI_final.pdf
  49. Lockwood CM, Pearson TA, Rees AJ, et al. Immunosuppression and plasma-exchange in the treatment of Goodpasture’s syndrome. Lancet. 1976;307(7962):711-715. doi:10.1016/S0140- 6736(76)93089-0
  50. Johnson JP, Moore J, Austin HA, Balow JE, Antonovych TT, Wilson CB. Therapy of anti- glomerular basement membrane antibody disease: Analysis of prognostic significance of clinical, pathologic and treatment factors. Med (United States). 1985;64(4):219-227. doi:10.1097/00005792-198507000-00003
  51. Lockwood CM, Boulton-Jones JM, Lowenthal RM, Simpson IJ, Peters DK. Recovery from Goodpasture’s syndrome after immunosuppressive treatment and plasmapheresis. Br Med J. 1975;2(5965):252-254. doi:10.1136/bmj.2.5965.252
  52. Peters DK, Rees AJ, Lockwood CM, Pusey CD. Treatment and prognosis in antibasement membrane antibody-mediated nephritis. Transplant Proc. 1982;14(3):513-521.
  53. Cui Z, Zhao J, Jia XY, et al. Anti-glomerular basement membrane disease: Outcomes of different therapeutic regimens in a large single-center chinese cohort study. Medicine (Baltimore). 2011;90(5):303-311. doi:10.1097/MD.0b013e31822f6f6854. Simpson I.J. et al. Plasma exchange in goodpasture’s syndrome // Am. J. Nephrol. 1982. Vol. 2, № 6. P. 301–311.
  54. Simpson IJ, Doak PB, Williams LC, et al. Plasma exchange in Goodpasture’s syndrome. Am J Nephrol. 1982;2(6):301-311. doi:10.1159/000166666
  55. Kidney. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl. 2013;3(1):1-150. http://www.kidney- international.org
  56. Schwartz J, Padmanabhan A, Aqui N, et al. Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue. J Clin Apher. 2016;31(3):149 - 162. doi:10.1002/jca.21470
  57. Williams ME, Balogun RA. Principles of separation: indications and therapeutic targets for plasma exchange. Clin J Am Soc Nephrol. 2014;9(1):181-190. doi:10.2215/CJN.04680513
  58. Zhang Y, Tang Z, Chen D, Gong D, Ji D, Liu Z. Comparison of double filtration plasmapheresis with immunoadsorption therapy in patients with anti-glomerular basement membrane nephritis. BMC Nephrol. 2014;15:128. doi:10.1186/1471-2369-15-128
  59. Pusey CD, Bowman C, Peters DK, Lockwood CM. Effects of cyclophosphamide on autoantibody synthesis in the Brown Norway rat. Clin Exp Immunol. 1983;54(3):697-704. Accessed November 13, 2019. http://www.ncbi.nlm.nih.gov/pubmed/6228357
  60. de Groot K, Harper L, Jayne DRW, et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med. 2009;150(10):670-680.
  61. Huart A, Josse A-G, Chauveau D, et al. Outcomes of patients with Goodpasture syndrome: A nationwide cohort-based study from the French Society of Hemapheresis. J Autoimmun. 2016;73:24-29. doi:10.1016/j.jaut.2016.05.015
  62. Jain R, Dgheim H, Bomback AS. Rituximab for Anti–Glomerular Basement Membrane Disease. Kidney Int Reports. 2019;4(4):614-618. doi:10.1016/j.ekir.2018.12.00263.
  63. van Daalen EE, Jennette JC, McAdoo SP, et al. Predicting outcome in patients with anti- GBM glomerulonephritis. Clin J Am Soc Nephrol. 2018;13(1):63-72. doi:10.2215/CJN.04290417
  64. Hind CR, Bowman C, Winearls CG, Lockwood CM. Recurrence of circulating anti- glomerular basement membrane antibody three years after immunosuppressive treatment and plasma exchange. Clin Nephrol. 1984;21(4):244-246.
  65. Liu P, Waheed S, Boujelbane L, Maursetter LJ. Multiple recurrences of anti-glomerular basement membrane disease with variable antibody detection: can the laboratory be trusted? Clin Kidney J. 2016;9(5):657-660. doi:10.1093/ckj/sfw038
  66. Gu B, Magil AB, Barbour SJ. Frequently relapsing anti-glomerular basement membrane antibody disease with changing clinical phenotype and antibody characteristics over time. Clin Kidney J. 2016;9(5):661-664. doi:10.1093/ckj/sfw048
  67. Keller F, Nekarda H. Fatal relapse in Goodpasture’s syndrome 3 years after plasma exchange. Respiration. 1985;48(1):62-66.
  68. Choy BY, Chan TM, Lai KN. Recurrent glomerulonephritis after kidney transplantation. Am J Transplant. 2006;6(11):2535-2542. doi:10.1111/j.1600-6143.2006.01502.x
  69. Tang W, McDonald SP, Hawley CM, et al. Anti-glomerular basement membrane antibody disease is an uncommon cause of end-stage renal disease. Kidney Int. 2013;83(3):503-510. doi:10.1038/ki.2012.375
  70. Douglas Briggs J, Jones E. Renal transplantation for uncommon diseases. Nephrol Dial Transplant. 1999;14(3):570-575. doi:10.1093/ndt/14.3.570
  71. Stern A, Green H, Paul M, Vidal L, Leibovici L. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane database Syst Rev. 2014;(10):CD005590. doi:10.1002/14651858.CD005590.pub37
  72. Mahr A, Girard T, Agher R, Guillevin L. Analysis of factors predictive of survival based on 49 patients with systemic Wegener’s granulomatosis and prospective follow-up. Rheumatology. 2001;40(5):492-498. doi:10.1093/rheumatology/40.5.492
  73. Bligny D, Mahr A, Toumelin P Le, Mouthon L, Guillevin L. Predicting mortality in systemic Wegener’s granulomatosis: A survival analysis based on 93 patients. Arthritis Care Res (Hoboken). 2004;51(1):83-91. doi:10.1002/art.20082
  74. Kronbichler A, Jayne DRW, Mayer G. Frequency, risk factors and prophylaxis of infection in ANCA-associated vasculitis. Eur J Clin Invest. 2015;45(3):346-368. doi:10.1111/eci.12410
  75. Matz E.L., Hsieh M.H. Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis // Urology. Elsevier Inc., 2017. Vol. 100. P. 16–19.76. Homik J. et al. Calcium and vitamin D for corticosteroid-induced osteoporosis // Cochrane Database Syst. Rev. Wiley, 1998. Vol. 1998, № 2.
  76. Homik J. et al. Calcium and vitamin D for corticosteroid-induced osteoporosis // Cochrane Database Syst. Rev. Wiley, 1998. Vol. 1998, № 2.
  77. Huart A, Josse A-G, Chauveau D, et al. Outcomes of patients with Goodpasture syndrome: A nationwide cohort-based study from the French Society of Hemapheresis. J Autoimmun. 2016;73:24-29. doi:10.1016/j.jaut.2016.05.015
  78. Alchi B, Griffiths M, Sivalingam M, Jayne D, Farrington K. Predictors of renal and patient outcomes in anti-GBM disease: clinicopathologic analysis of a two-centre cohort. Nephrol Dial Transplant. 2015;30(5):814-821. doi:10.1093/ndt/gfu399

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*